Panel Discussion Points:

• Is complete lung regeneration achievable, or is the primary goal to halt further tissue damage and improve function in IPF?
• What are the potential risks (e.g., tumorigenesis, stem cell activation) versus the promising benefits of regenerative therapies?
• Which biomarkers are crucial to track and validate the success of regenerative approaches in IPF?
• How can insights from tissue engineering, oncology, and other regenerative medicine areas inform and advance lung regeneration therapies for IPF?
• Which regenerative approaches are showing real potential for recovery versus those focusing on disease modification in the IPF treatment landscape?